ReviewArchivos de cardiologia de Mexico2025
Clinical relevance and management of atrial high-rate episodes: a narrative review.
Review in Archivos de cardiologia de Mexico, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Incremental predictive value of device and echocardiographic parameters for atrial high-rate episodes: a prospective cohort study.BMC cardiovascular disorders · 2026Article
- The Role of High-Sensitivity Troponin I in Predicting Atrial High-Rate Episodes (AHREs) in Patients with Permanent Pacemakers.Life (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial high-rate episodes (AHREs) are atrial tachyarrhythmias detected by cardiac implantable electronic devices when the atrial rate exceeds the device's programmed detection threshold. The frequency and duration of these episodes vary, with those lasting more than 5 min generally considered clinically significant. The occurrence of AHREs has been associated, in multiple clinical trials, with an increased risk of progression to overt atrial fibrillation (AF) and a higher incidence of thromboembolic events, particularly ischemic stroke. Several studies have demonstrated that the strength of these associations is directly proportional to AHREs duration and is further influenced by comorbidities such as advanced age, hypertension, and a history of heart failure. Despite the elevated embolic risk, clinical uncertainty persists regarding the optimal timing and indication for initiating long-term oral anticoagulation in patients with AHREs. Consequently, this narrative review aims to outline a contemporary clinical approach and propose a treatment algorithm for AHREs, grounded in the current body of evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.